title: Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer.
abstract: A Phase II study of yttrium-90-tetra-azacyclododecanetetra-acetic acid-biotin (90Y-DOTA-biotin) pretargeted by NR-LU-10 antibody/streptavidin (SA) was performed. The primary objectives of the study were to evaluate the efficacy and safety of this therapy in patients with metastatic colon cancer. Twenty-five patients were treated with a single dose of 110 mCi/m2 (mean administered dose, 106.5 +/- 10.3 mCi/m2) of 90Y-DOTA-biotin. There were three components of the therapy. Patients first received NR-LU-10/SA on day 1. A clearing agent (biotin-galactose-human serum albumin) was administered approximately 48 h after the NR-LU-10/SA to remove residual circulating unbound NR-LU-10/SA. Lastly, 24 h after administration of clearing agent, patients received biotin-DOTA-labeled with 110 mCi/m2 90Y. All three components of the therapy were administered i.v. Both hematological and nonhematological toxicities were observed. Diarrhea was the most frequent grade 4 nonhematological toxicity (16%; with 16% grade 3 diarrhea). Hematological toxicity was less severe with 8% grade 3 and 8% grade 4 neutropenia and 8% grade 3 and 16% grade 4 thrombocytopenia. The overall response rate was 8%. Two partial responders had freedom from progression of 16 weeks. Four patients (16%) had stable disease with freedom from progression of 10-20 weeks. Despite the relatively disappointing results of this study in terms of therapeutic efficacy and toxicity, proof of principle was obtained for the pretargeting approach. In addition, valuable new information was obtained about normal tissue tolerance to low-dose-rate irradiation that will help to provide useful guidelines for future study designs.
authors.affiliation: Stanford University School of Medicine, Department of Radiation Oncology, California 94305, USA.
authors.forename: S J
authors.initials: SJ
authors.lastname: Knox
authors.forename: M L
authors.initials: ML
authors.lastname: Goris
authors.forename: M
authors.initials: M
authors.lastname: Tempero
authors.forename: P L
authors.initials: PL
authors.lastname: Weiden
authors.forename: L
authors.initials: L
authors.lastname: Gentner
authors.forename: H
authors.initials: H
authors.lastname: Breitz
authors.forename: G P
authors.initials: GP
authors.lastname: Adams
authors.forename: D
authors.initials: D
authors.lastname: Axworthy
authors.forename: S
authors.initials: S
authors.lastname: Gaffigan
authors.forename: K
authors.initials: K
authors.lastname: Bryan
authors.forename: D R
authors.initials: DR
authors.lastname: Fisher
authors.forename: D
authors.initials: D
authors.lastname: Colcher
authors.forename: I D
authors.initials: ID
authors.lastname: Horak
authors.forename: L M
authors.initials: LM
authors.lastname: Weiner
mesh_terms: D000328:Adult; D000368:Aged; D000740:Anemia / Q000209:etiology; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000633:toxicity*; D001710:Biotin / Q000008:administration & dosage / Q000031:analogs & derivatives; D003110:Colonic Neoplasms / Q000473:pathology / Q000532:radiotherapy*; D005260:Female; D006801:Humans; D007970:Leukopenia / Q000209:etiology; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009942:Organometallic Compounds / Q000008:administration & dosage; D016499:Radioimmunotherapy; D019275:Radiopharmaceuticals / Q000009:adverse effects / Q000627:therapeutic use*; D013921:Thrombocytopenia / Q000209:etiology; D015021:Yttrium Radioisotopes / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D000911:Antibodies, Monoclonal; C405616:DOTA-biotin; C405617:NR-LU-10 antibody; D009942:Organometallic Compounds; D019275:Radiopharmaceuticals; D015021:Yttrium Radioisotopes; D001710:Biotin